Trial Profile
An Open-Label, Single-Arm Phase III Study to Evaluate the Efficacy, Safety and Tolerability of TMC435 in Combination With PegIFN Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment-Naïve or Treatment-Experienced, Chronic Hepatitis C Virus Genotype-4 Infected Subjects.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Simeprevir (Primary) ; Peginterferon alfa-2a; Ribavirin
- Indications Hepatitis C
- Focus Registrational; Therapeutic Use
- Acronyms RESTORE
- Sponsors Janssen R&D Ireland
- 14 Apr 2014 According to the ClinicalTrials.gov record, status changed from active, no longer recruiting to completed.
- 24 Mar 2014 Results will be presented at The International Liver Congress of the European Association for the study of the Liver (EASL) according to a Medivir AB media release.
- 11 Jan 2014 European Clinical Trials Database record reports status as recruiting.